PackGene Biotech, Inc.’s Post

🔬 Exciting News in Cell and Gene Therapy Manufacturing! 💡 Limula has secured $6.8 million in funding to enhance its cell and gene therapy manufacturing capabilities. This funding will be pivotal in advancing Limula's innovative solutions, making cell and gene therapies more accessible and efficient. Key Highlights: Funding Amount: $6.8 million Purpose: To enhance and streamline cell and gene therapy manufacturing processes Impact: This investment will help Limula scale up its production capabilities, improve manufacturing efficiency, and support the development of advanced therapies for patients. This funding is set to drive significant advancements in the cell and gene therapy sector, offering new hope for patients requiring these cutting-edge treatments. Read more about this exciting development here: https://lnkd.in/gkQSDs_m #Biotech #CellTherapy #GeneTherapy #Funding #Innovation #Limula #Healthcare #MedicalResearch #Therapeutics

While cell and gene therapies have been revolutionary for thousands of patients, as many as 95% of those who could benefit lack access because of production barriers. Enter Ori Biotech.  In late May, Ori introduced its IRO platform, a technology that aims to accelerate the manufacturing of cell and gene therapies while reducing labor and production costs. The platform brings together three key components: Automation, a unique bioreactor system and a cloud-native digital capability, which captures and processes data every seven seconds.  While it remains to be seen if Ori’s IRO platform can reach its lofty goal of making cell and gene therapies more affordable and accessible, it’s encouraging that companies are pursuing vital innovations in this space. My ZS colleagues have been tracking the cell and gene landscape in anticipation of a tripling of therapies becoming available by 2030. Take a look at our article, which I've linked to in the comments. https://lnkd.in/dDM6pHFw 

🧬 𝐏𝐚𝐬𝐭, 𝐩𝐫𝐞𝐬𝐞𝐧𝐭, 𝐚𝐧𝐝 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 Gene therapy was and is transformative. Starting with the EMA and FDA approvals in 2009 and 2010, through to recent CRISPR-based technologies, it shows that the development of this area is accelerating. There are still some issues to solve, such as undesired immune responses or complex delivery mechanisms, but I believe that in the near future, we will see the incorporation of gene and cell therapies into more therapeutic areas. A very nice read: https://lnkd.in/dWq8EBzi #biotech #pharma #genetherapy #geneediting #funding #womeninbusinesss #drjojo ---------- Hi! I am Joanna, and my friends call me Dr Jojo 🌸 𝐈 𝐭𝐚𝐥𝐤 𝐚𝐛𝐨𝐮𝐭 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 𝐚𝐧𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 ♻️ Share this if you find it interesting 🔔 Follow for insights you won't want to miss

DataHow, as part of a Swiss and UK consortium, has been awarded a grant from Innovate UK and Innosuisse to accelerate innovation in cell and gene therapy manufacturing. The consortium, comprising the Cell and Gene Therapy Catapult, Securecell AG, and DataHow AG, has been awarded the grant to integrate new digitisation and process analytical technologies (PATs) into the manufacturing of cell and gene therapies. The project is additionally supported by ChemoMetec A/S and HORIBA UK LIMITED. Bioprocess data will be transferred to DataHow's DataHowLab software for in-silico process development and real-time predictions. The project aims to integrate advanced PATs into an AAV gene therapy manufacturing process. This collaboration seeks to enhance process monitoring, control, and optimization in cell and gene therapy manufacturing. The primary objectives are to improve product quality, increase production efficiency, reduce costs, and speed the delivery of gene therapies to patients. #Innovation #CellTherapy #GeneTherapy #Bioprocessing #ProcessOptimization #DigitalTransformation #HealthcareInnovation #PATs

Are you ready to explore cutting-edge gene delivery and gene editing technologies that will future-proof your therapeutic development? Join our upcoming free webinar, sponsored by Revvity, to master innovative solutions and understand their crucial role in advancing gene therapies while enhancing efficiency. The Challenge You Face: Navigating complex gene delivery and editing advancements can be overwhelming, with rapidly evolving methods and therapeutic applications. The Shortcomings of Traditional Methods: Traditional gene delivery systems often face limitations in efficiency, cost, and specificity. With ongoing developments, these outdated methods may no longer meet the demands of advanced cell and gene therapies, leading to inefficiencies and higher operational costs. The Solution We Offer: Implementing advancements in gene therapy, such as AAV evolution, LentBOOST™ transduction enhancer, and Revvity’s Pin-point™ base editing platform, will optimise your processes. By integrating these technologies, you’ll stay compliant with industry advancements, future-proof your therapeutic pipelines, and significantly improve operational efficiency. Why Attend Our Webinar? Join us for an expert-level session featuring an industry leader who will break down the latest developments in AAV evolution, lentiviral enhancement, and gene editing approaches. Learn how you can incorporate these technologies into new and existing systems to stay competitive in 2024 and beyond. > Thursday, 5th December 2024 > 3PM London / 10AM New York REGISTER HERE > https://lnkd.in/eatiYRab

Ori Biotech Reveals Automated Platform for Cell & Gene Therapy Production Ori Biotech a cell and gene therapy (CGT) #manufacturing technology producer, recently announced the commercial launch of IRO, a next-generation platform. Manufacturing remains a critical barrier to scaling #CGTs, limiting the clinical and commercial impact of this life-saving new class of #therapies. Ori Biotech has developed the IRO platform as part of its mission to enable widespread patient access to life-saving CGTs. “A new wave of cell and gene therapies holds immense promise for patients; however, to achieve the true #clinical impact, therapies must be not only approvable but also accessible and affordable,” commented Jason C. Foster, CEO, Ori Biotech. “Over the last five years, we’ve focused on Biology First, generating best-in-class #biological data from over 500 runs with ten different partners, across different cell types and protocols to demonstrate how the IRO platform can Automate Better Biology. For too long, scientists and therapy developers have had to sacrifice biological performance for automation, not anymore.” Read more on #CMI online: https://lnkd.in/eYSUPwzn

I've been seeing a lot about Ori Biotech's IRO cell and gene therapy manufacturing platform. With over 95% of patients left without access to cell and gene therapies, overcoming current challenges in manufacturing remains a critical barrier to scaling cell and gene therapies. The platform has the potential to shave years off therapy development timelines, reducing labor by up to 70%, reducing the cost of goods by up to 50%, cutting processing times by up to 25%, and accelerating #tech transfer times from months to weeks. The IRO platform is a keen example of how #biotech is working to enable widespread patient access to life-saving therapies.

1) Calling for better delivery vectors (than AAV). 2) Treatment window: before immune system reaches maturity? 3) Scope: What about diseases (conditions) not caused by single mutation.

🚀 Advances in AAV Manufacturing for Gene Therapy! Gene therapy has made incredible strides, but scaling up AAV production for broad accessibility is still a challenge. From plasmid construction to AAV vector production and purification, each step impacts therapeutic quality and cost. Our blog dives into the nuances of the AAV manufacturing process and the innovative solutions helping to optimize production, reduce impurities, and ensure therapeutic efficacy. Discover how advances like Form Bio’s AI-driven In Silico Assays™ and new methods in quality control are paving the way for efficient, scalable gene therapy. Read more! https://hubs.li/Q02YhLYD0 #genetherapy #AAV #AI #insilico

🌟 Meeting on the Mesa: Shaping the Future of Cell and Gene Therapy 🌟 The annual "Meeting on the Mesa" continues to be a pivotal event for the cell and gene therapy industry. As we explore groundbreaking opportunities, the challenges remain as significant as the potential. This year’s discussions will dive into: 🔬 The latest innovations in cell and gene therapies   💼 Scaling production to meet global demand   ⚖️ Navigating regulatory landscapes   💡 Addressing the talent gap in this rapidly evolving field The intersection of scientific breakthroughs and strategic challenges creates a unique moment for growth. With the right collaboration, the future of healthcare can be transformed. 🌐 Excited to see what’s next! What are your thoughts on the key challenges and opportunities in this space? Share below! 👇 #CellTherapy #GeneTherapy #Biotech #Innovation #MeetingOnTheMesa #HealthcareTransformation https://lnkd.in/gbEYkJwF